Back to Search Results

The Effects of Coenzyme Q10 Supplementation on Oxidative Status and Lipid Profile in Migraine Patients: A Randomized Double-Blinded Controlled Clinical Trial.

Department of Nutrition Sciences, Varastegan Institute of Medical Sciences, Mashhad 9179667680, Iran. Health Sciences Research Center, Torbat Heydariyeh University of Medical Sciences, Torbat Heydariyeh 9516915169, Iran. Department of Nutrition, Food Sciences and Clinical Biochemistry, School of Medicine, Social Determinants of Health Research Center, Gonabad University of Medical Sciences, Gonabad 9691793718, Iran. Department of Neurology, Tabriz University of Medical Sciences, Tabriz 5166614711, Iran. Department of Statistics and Epidemiology, Faculty of Health, Tabriz University of Medical Sciences, Tabriz 5166614711, Iran. Road Traffic Injury Research Center, Tabriz University of Medical Sciences, Tabriz 5166614711, Iran. Department of Nutrition, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad 1394491388, Iran. Nutrition Research Center, School of Nutrition and Food Sciences, Tabriz University of Medical Sciences, Tabriz 5166614711, Iran.

Clinical nutrition research. 2023;(4):257-268
Full text from:

Other resources

Abstract

UNLABELLED Migraine is a common neurological disease correlated with oxidative stress and lipid profile disorders. The present study was designed to determine the effects of Coenzyme Q10 (Co-Q10) supplementation on oxidative status and lipid profile in migraine individuals. This clinical trial was conducted on 84 females aged 18-50 years, diagnosed for episodic migraine according to the International Headache Society. Subjects were randomized to receive either Co-Q10 supplement (400 mg/day) or placebo for 12 weeks. Lipid profile and oxidative stress indices including malondialdehyde (MDA) and total antioxidant capacity (TAC) were measured before and after intervention in both groups. Also, anthropometric indices, dietary intakes, and clinical features were collected. Data analysis was conducted using SPSS version 16. Seventy-seven of the participants, with mean age of 33.70 ± 7.75 years, completed the study. After 12-week intervention, Co-Q10 led to a significant decrease in MDA levels compared to placebo (p = 0.009), with no effect on TAC levels (p = 0.106). A significant increase in serum Co-Q10 concentration and high-density lipoprotein cholesterol (HDL-C) level in Co-Q10 group was observed, but no significant differences were found in other lipid profile variables (low-density lipoprotein cholesterol, triglycerides and total cholesterol). Among anthropometric variables, Co-Q10 only caused a significant reduction in body fat percentage (BFP), but we did not find any significant changes in others. A 12-week Co-Q10 supplementation led to significant improvement in clinical features, BFP, and HDL-C level among migraine individuals. TRIAL REGISTRATION Iranian Registry of Clinical Trials Identifier: IRCT201508265670N10.